1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Cavernous Angioma, Central Nervous System in 4 studies
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The phenotypic manifestations of cerebral cavernous malformation disease caused by rare PDCD10 mutations have not been systematically examined, and a mechanistic link to Rho kinase-mediated hyperpermeability, a potential therapeutic target, has not been established." | 1.42 | Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. ( Akers, AL; Austin, C; Awad, IA; De Souza, JM; Gallione, CJ; Gunel, M; Lee, C; Marchuk, DA; McDonald, DA; Mikati, AG; Min, W; Rebeiz, T; Rorrer, A; Shenkar, R; Shi, C; Stockton, RA; Zhang, L, 2015) |
| "Familial cerebral cavernous malformations (CCMs) in humans result from mutations of CCM2 (malcavernin, OSM, MGC4607), PDCD10 (CCM3), or KRIT1 (CCM1), a Rap1 effector which stabilizes endothelial cell-cell junctions." | 1.36 | Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity. ( Awad, IA; Ginsberg, MH; Shenkar, R; Stockton, RA, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Detter, MR | 1 |
| Shenkar, R | 4 |
| Benavides, CR | 1 |
| Neilson, CA | 1 |
| Moore, T | 2 |
| Lightle, R | 2 |
| Hobson, N | 1 |
| Shen, L | 1 |
| Cao, Y | 2 |
| Girard, R | 2 |
| Zhang, D | 1 |
| Griffin, E | 1 |
| Gallione, CJ | 2 |
| Awad, IA | 4 |
| Marchuk, DA | 3 |
| Shi, C | 2 |
| Rebeiz, T | 1 |
| Stockton, RA | 2 |
| McDonald, DA | 2 |
| Mikati, AG | 1 |
| Zhang, L | 2 |
| Austin, C | 2 |
| Akers, AL | 1 |
| Rorrer, A | 2 |
| Gunel, M | 1 |
| Min, W | 1 |
| De Souza, JM | 1 |
| Lee, C | 1 |
| Wu, M | 1 |
| Zeineddine, HA | 1 |
| Gallione, C | 1 |
| Pytel, P | 1 |
| Liao, JK | 1 |
| Ginsberg, MH | 1 |
4 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Cavernous Angioma, Central Nervous System
| Article | Year |
|---|---|
Novel Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute Disease; Animals; Apoptosis Regulatory Proteins | 2020 |
Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Animals; Apoptosis Regulatory Prot | 2015 |
RhoA Kinase Inhibition With Fasudil Versus Simvastatin in Murine Models of Cerebral Cavernous Malformations.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Brain Neoplasms; Disease Models, Animal; Fem | 2017 |
Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animal Structures; Animals; Brain Edema; Capillary Pe | 2010 |